Penumbra (PEN)

• Market cap: $9.84B
• 1 day: -1.52%
• 5 days: -8.14%
• 1 month: -1.16%
• 3 months: -1.79%
• 6 months: -8.31%
• Year to date: 5.17%
• 1 year: 29.05%
• 5 years: 22.54%
• 10 years: 511.14%
• Sector: Healthcare
• Industry: Medical Devices

About: Domiciled in the US, Penumbra designs, manufactures, and markets an array of thrombectomy and embolization devices and equipment to mechanically remove blood clots. The firm sells mainly to hospitals and physicians. These minimally invasive devices are primarily used in the acute care setting for patients with stroke, pulmonary embolism, deep vein thrombosis, cranial aneurysms, and other vascular diseases.

Employees: 4,500

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

405% more call options, than puts

Call options by funds: $73.2M | Put options by funds: $14.5M

67% more first-time investments, than exits

New positions opened: 85 | Existing positions closed: 51

19% more repeat investments, than reductions

Existing positions increased: 166 | Existing positions reduced: 139

6% more funds holding

Funds holding: 417 [Q1] → 444 (+27) [Q2]

2.27% more ownership

Funds ownership: 90.07% [Q1] → 92.33% (+2.27%) [Q2]

1% less capital invested

Capital invested by funds: $9.28B [Q1] → $9.17B (-$106M) [Q2]

50% less funds holding in top 10

Funds holding in top 10: 6 [Q1] → 3 (-3) [Q2]

Research analyst outlook

8 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $266
• Avg. target: $308
• High target: $350

8 analyst ratings

• positive: 6 75%
• neutral: 2 25%
• negative: 0 0%

Evercore ISI Group Vijay Kumar	$300	Outperform Initiated	2 Sep 2025
Morgan Stanley Kallum Titchmarsh	$266	Equal-Weight Maintained	31 Jul 2025
Truist Securities David Rescott	$310	Buy Maintained	30 Jul 2025
UBS Priya Sachdeva	$335	Buy Maintained	30 Jul 2025
RBC Capital Shagun Singh	$325	Outperform Maintained	30 Jul 2025